@article{4ab17566ce4b4c3c8e29fe683dab07a7,
title = "Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients–evidence from a large observational cohort",
abstract = "letter, not available",
keywords = "Antiretroviral Therapy, Atazanavir Sulfate, Darunavir, HIV, HIV Infections, Highly Active, Humans, Lamivudine, Ritonavir, Antiretroviral Therapy, Atazanavir Sulfate, Darunavir, HIV, HIV Infections, Highly Active, Humans, Lamivudine, Ritonavir",
author = "Bavaro, {D. F.} and Di, {Carlo D.} and P. Zuccala and F. Bai and F. Incardona and A. Battisti and S. Giache and E. Salomoni and R. Gagliardini and {Di Giambenedetto}, Simona and M. Pecorari and M. Zazzi and De, {Luca A.} and A. Bezenchek and Lo, {Caputo S.}",
year = "2019",
doi = "10.1080/23744235.2018.1544423",
language = "English",
volume = "51",
pages = "234--239",
journal = "Infectious Diseases",
issn = "2374-4235",
publisher = "Taylor and Francis Ltd.",
number = "3",
}